Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 47

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 47
---
 following the completion of the Merger, which may have an adverse effect on the ability of each of MIRA and SKNY to motivate or retain management personnel and other key employees. In addition, no assurance can be given that MIRA will be able to attract, motivate or retain management personnel and other key employees to the same extent that SKNY had previously been able. If management personnel or other key employees terminate their employment, MIRA’s business activities may be adversely affected, and management’s attention may be diverted from successfully integrating MIRA and SKNY which may cause MIRA’s progress to suffer.

MIRA will incur significant transaction and integration-related costs in connection with the Merger, which could adversely affect MIRA’s ability to execute its integration plan and achieve the anticipated benefits of the Merger.

MIRA expects to incur a number of non-recurring costs associated with the Merger and combining the operations of the two companies. MIRA continues to assess the magnitude of these Merger and integration-related costs, and additional unanticipated

costs may also be incurred. Although MIRA expects that the elimination or avoidance of duplicative costs, as well as the realization of other efficiencies related to the integration of the businesses of MIRA and SKNY, should allow SKNY to offset integrationrelated costs over time, this net benefit may not be achieved in the near term or at all.

The market price of MIRA Common Stock may decline as a result of the Merger and the issuance of shares of MIRA Common Stock to SKNY stockholders in the Merger may have a negative impact on MIRA’s financial results, including future earnings per share.

The market price of MIRA Common Stock may decline as a result of the Merger, and holders of MIRA Common Stock (including holders of SKNY Common Stock who receive MIRA Common Stock) could see a decrease in the value of their

investment holdings if, among other things, MIRA is unable to achieve the expected growth in earnings, or if the anticipated benefits, including synergies, cost savings, innovation and operational efficiencies, from the Merger are not realized, or if the Merger and integration-related costs related to the Merger are greater than expected. The market price of MIRA Common Stock may also decline if MIRA does not achieve the anticipated benefits of the Merger as rapidly or to the extent expected by financial or industry analysts or if the effects of the Merger on MIRA’s financial position, results of operations or cash flows are not otherwise consistent with the expectations of financial